![Anders Hinsby](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anders Hinsby
Directeur des opérations chez
Muna Therapeutics ApS
Profil
Anders Mørkebjerg Hinsby founded Orphazyme A in 2009, where he worked as Chief Executive Officer from 2009 to 2019.
Dr. Hinsby also currently works at Intomics A, as Director from 2019, Vico Therapeutics BV, as Independent Director from 2020, WoB Holding ApS, as Member-Management Board, and Muna Therapeutics ApS, as Chief Operating Officer from 2021.
Dr. Hinsby also formerly worked at Dansk Biotek, as Chief Executive Officer & Director, F2G Ltd., as Non-Executive Director, Oz Holding ApS, as Director, BI Technology A, as Partner from 2009 to 2010, Technical University of Denmark, as Assistant Professor, Novo Ventures 1 A, as Principal, Bankinvest Biomedical Venture, as Principal, and InnovationsFonden, as Member.
Dr. Hinsby received his doctorate degree from the University of Copenhagen.
Postes actifs de Anders Hinsby
| Sociétés | Poste | Début |
|---|---|---|
WoB Holding ApS
 WoB Holding ApS Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | - |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Develops ribonucleic acid modulating therapies | Directeur/Membre du Conseil | 01/10/2020 |
Muna Therapeutics ApS
 Muna Therapeutics ApS BiotechnologyHealth Technology Engages in discovering and developing of therapies that slow and stop devastating neurodegenerative, alzheimer’s & parkinson’s diseases | Directeur des opérations | 01/07/2021 |
Intomics A/S
 Intomics A/S Miscellaneous Commercial ServicesCommercial Services Provides data analysis solutions to data intensive research projects | Directeur/Membre du Conseil | 01/01/2019 |
Anciens postes connus de Anders Hinsby
| Sociétés | Poste | Fin |
|---|---|---|
| STRATEGIC PARTNERS A/S | Directeur Général | 01/10/2019 |
BI Technology A/S
 BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Private Equity Investor | 01/01/2010 |
Oz Holding ApS
 Oz Holding ApS Financial ConglomeratesFinance Provides investment services | Directeur/Membre du Conseil | - |
InnovationsFonden
 InnovationsFonden Investment ManagersFinance Innovations Fonden invests in companies across the globe. The firm focuses on a broad range of sectors and industries. It participates in buyout transactions. | Corporate Officer/Principal | - |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Operates as an industry association for biotech companies with promoting the biotechnological research | Directeur Général | - |
Formation de Anders Hinsby
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
24
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
BI Technology A/S
BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Finance |
Technical University of Denmark
 Technical University of Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Health Technology |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements. | Finance |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Operates as an industry association for biotech companies with promoting the biotechnological research | Commercial Services |
Strategic Partners A/S
 Strategic Partners A/S Pharmaceuticals: MajorHealth Technology Provides therapeutic treatment of of diseases caused by defects in the function and metabolism of proteins | Health Technology |
Intomics A/S
Intomics A/S Miscellaneous Commercial ServicesCommercial Services Provides data analysis solutions to data intensive research projects | Commercial Services |
Bankinvest Biomedical Venture
 Bankinvest Biomedical Venture Investment ManagersFinance Operates as venture capital firm | Finance |
InnovationsFonden
InnovationsFonden Investment ManagersFinance Innovations Fonden invests in companies across the globe. The firm focuses on a broad range of sectors and industries. It participates in buyout transactions. | Finance |
WoB Holding ApS
WoB Holding ApS Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Oz Holding ApS
Oz Holding ApS Financial ConglomeratesFinance Provides investment services | Finance |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Develops ribonucleic acid modulating therapies | Health Technology |
Muna Therapeutics ApS
Muna Therapeutics ApS BiotechnologyHealth Technology Engages in discovering and developing of therapies that slow and stop devastating neurodegenerative, alzheimer’s & parkinson’s diseases | Health Technology |
